
Keywords: فاز اول; AEs; adverse events; ELISA; enzyme-linked immunosorbent assay; SD; standard deviation; TEAEs; treatment emergent adverse events; TMB; 3,3â²,5,5â²-tetramethylbenzidine; EPT; end-point titre; MSD; mesoscale discovery; ECL; electrochemiluminescence; Ply; p